Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $AGEN alert in real time by email

Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the company with enhanced operational flexibility during this pivotal period.

Key Measures Include:

  • Focusing on BOT/BAL: Agenus will concentrate its resources on its lead botensilimab/balstilimab (BOT/BAL) program, which has demonstrated robust clinical activity in microsatellite stable colorectal cancer (MSS CRC), non-small cell lung cancer (NSCLC), pancreatic cancer, sarcoma, and other difficult-to-treat cancers.
  • Reducing Costs: The company will implement significant cost-cutting measures, including staff reductions and operational adjustments, targeting a 60% reduction in annual expenditures and a cash burn of $100 million for FY 2025.
  • Optimizing Expert Manufacturing Capabilities: Agenus plans to transition its biologics CMC capabilities to a fee-for-service model, unlocking new revenue opportunities. This initiative is intended to be supported by external funding.

"These adjustments are necessary to position Agenus for success in a challenging biotech environment," said Dr. Garo Armen, Chairman and CEO of Agenus. "We remain committed to advancing BOT/BAL for patients with cancers that have limited or no treatment options."

BOT/BAL continues to demonstrate potential across multiple cancer types, particularly MSS CRC, a cancer historically unresponsive to existing treatments. Agenus is advancing BOT/BAL through clinical development and preparing for global regulatory submissions.

Supporting Employees

Agenus is grateful to the contributions of all our team members and will be providing support and assistance to affected employees to help with their transitions, reflecting the company's appreciation for their contributions.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

About Botensilimab (BOT)

Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Get the next $AGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What program is Agenus prioritizing in its strategic realignment?

    Agenus Inc. is focusing its resources primarily on its lead botensilimab/balstilimab (BOT/BAL) program, which has shown clinical activity in various difficult-to-treat cancers, including microsatellite stable colorectal cancer.

  • What are the financial targets Agenus has set as part of their reorganization?

    Agenus aims to reduce its cash burn to $100 million for FY 2025 by implementing significant cost-cutting measures, including staff reductions and operational adjustments, targeting a total reduction of 60% in annual expenditures.

  • How is Agenus looking to optimize its manufacturing capabilities?

    The company plans to transition its biologics CMC capabilities to a fee-for-service model, which is expected to unlock new revenue opportunities and will be supported by external funding.

  • What is Dr. Garo Armen's perspective on the recent changes at Agenus?

    The CEO, Dr. Garo Armen, emphasized that these adjustments are necessary for success in a challenging biotech environment and reaffirmed commitment to advancing BOT/BAL for patients with limited treatment options.

  • How is Agenus addressing the impact of its staff reductions on employees?

    Agenus plans to provide support and assistance to affected employees to help them transition, reflecting gratitude for their contributions to the company.

Recent Analyst Ratings for
$AGEN

DatePrice TargetRatingAnalyst
7/19/2024$35.00 → $8.00Outperform → Neutral
Robert W. Baird
7/18/2024Outperform → Mkt Perform
William Blair
7/18/2024$9.00Buy → Neutral
H.C. Wainwright
6/6/2023$8.00Outperform
Robert W. Baird
6/6/2023$60.00 → $80.00Outperform
Robert W. Baird
2/28/2023$8.00Buy
H.C. Wainwright
9/28/2022$5.00Outperform
SMBC Nikko
3/2/2022$12.00 → $14.00Buy
HC Wainwright & Co.
More analyst ratings

$AGEN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

    First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT/BAL Phase 1 trial to be presented Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus' neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

    Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options CRC Diagnoses Rise While Current Standards Fall Short Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care. Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system alike.1 The Colorectal Cancer in Focus survey, conducted online in the U.S. from

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

    Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AGEN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGEN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGEN
SEC Filings

See more

$AGEN
Leadership Updates

Live Leadership Updates

See more
  • Agenus Announces Appointment of Tom Harrison to Board of Directors

    Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

    Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus Expands Executive Leadership Team

    Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AGEN
Financials

Live finance-specific insights

See more
  • Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

    Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

    Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

    Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by

    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AGEN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more